Connect with us

Government

Nationwide Surge In Deaths Among People Aged 18-49: A State By State Overview

Nationwide Surge In Deaths Among People Aged 18-49: A State By State Overview

Authored by Petr Svab via The Epoch Times (emphasis ours),

Deaths among people aged 18 to 49 increased more than 40 percent in the 12 months ending October 2021…

Published

on

Nationwide Surge In Deaths Among People Aged 18-49: A State By State Overview

Authored by Petr Svab via The Epoch Times (emphasis ours),

Deaths among people aged 18 to 49 increased more than 40 percent in the 12 months ending October 2021 compared to the same period in 2018–2019, before the COVID-19 pandemic, according to an analysis of death certificate data from the Centers for Disease Control and Prevention (CDC) by The Epoch Times.

First responders load a patient into an ambulance from a nursing home where multiple people have contracted COID-19 on April 17, 2020 in Chelsea, Massachusetts. (Scott Eisen/Getty Images)

The agency doesn’t yet have full 2021 numbers, as death certificate data trickles in with a lag of one to eight weeks or more.

The increase was notable across the country and in no state was COVID reported in more than 60 percent of the excess deaths. Some states experienced much steeper hikes than others.

Nevada was the worst with a 65 percent prime-age mortality surge of which only 36 percent was attributed to COVID. Texas was second with a 61 percent jump of which 58 percent was attributed to COVID. Arizona and Tennessee recorded 57 percent increases with 37 percent and 33 percent attributed to COVID respectively. Not far behind was California at 55 percent and 42 percent attributed to COVID as well as New Mexico (52 percent, 33 percent), Florida (51 percent, 48 percent), and Louisiana (51 percent, 32 percent).

On the other side of the spectrum was New Hampshire with no mortality increase and no COVID deaths in this age group and Delaware with a 10 percent mortality increase, zero attributed to COVID. Massachusetts had only a 13 percent spike with 24 percent of it attributed to COVID and Maryland had a 16 percent jump, 42 percent attributed to COVID. Close behind were Connecticut, Hawaii, and New Jersey with 17 percent increases (23 percent, 45 percent, 58 percent attributed to COVID respectively).

CDC data on the exact causes of those excess deaths aren’t yet available for 2021, aside from those involving COVID, pneumonia, and influenza. There were close to 6,000 excess pneumonia deaths that didn’t involve COVID-19 in the 18–49 age group in the 12 months ending October 2021. Influenza was only involved in 50 deaths in this age group, down from 550 in the same period pre-pandemic. The flu death count didn’t exclude those that also involved COVID or pneumonia, the CDC noted.

Medics wait to transport a woman with possible Covid-19 symptoms to the hospital in Austin, Texas, on Aug. 07, 2020. (John Moore/Getty Images)

It’s not clear why the mortality spike seemed to exhibit a geographical trend. Overall, a part of the surge could be likely blamed on drug overdoses, which increased to more than 101,000 in the 12 months ending June 2021 from about 72,000 in 2019, the CDC estimated. About two-thirds of those deaths involved synthetic opioids including fentanyl that are often smuggled to the United States from China through Mexico.

For those ages 50 to 84, mortality went up more than 27 percent, representing more than 470,000 excess deaths. Almost four out of five of the deaths had COVID marked on the death certificate as the cause or a contributing factor.

For those 85 or older, mortality increased about 12 percent with more than 100,000 excess deaths. With more than 130,000 COVID-related deaths in this group, the data indicates that these seniors were less likely to die of a non-COVID-related cause from November 2020 to October 2021 than during the same period of 2018–2019.

Health care workers tend to a patient in Apple Valley, Califironia, on Jan. 11, 2021. (ARIANA DREHSLER/AFP via Getty Images)

Comparing 2020 to 2019, mortality increased some 24 percent for those 18–49, with less than a third of those excess deaths involving COVID. For those 50–84, it increased less than 20 percent, with over 70 percent of that involving COVID. For those even older, mortality jumped about 16 percent, with nearly 90 percent of that involving COVID.

For those under 18, mortality decreased about 0.4 percent in 2020 compared to 2019. In the 12 months ending October 2021, it fell some 3.3 percent compared to the same period in 2018–2019.

Tyler Durden Thu, 01/13/2022 - 17:00

Read More

Continue Reading

Spread & Containment

Don’t believe the claim that only 17,371 people have died from COVID in England and Wales

A freedom of information request is only useful if you know how to read the data.

Published

on

There is no doubt that the pandemic has led to many deaths; however, in the past week, new claims have emerged that the true number of people who have died from COVID in England and Wales is much lower than previously thought. These claims have been widely shared on social media and even amplified by a senior MP. Can it really be true that new data shows that COVID has killed far fewer people than we previously thought?

To arrive at an answer, we first need to delve into the various ways that COVID deaths are counted in England and Wales. There are two main sources of this data: the first, published by the UK Health Security Agency (UKHSA) and featured prominently on the government’s coronavirus dashboard, is a simple count of all deaths that occur within 28 days of a positive COVID test.

The second, published by the Office for National Statistics (ONS) is based on death certificates that list COVID as a cause of death. Being based on a medical assessment of the circumstances of each individual death, the ONS figures represent the gold standard.

The UKHSA figures will include some deaths that are clearly unrelated to COVID – for example, somebody who has a mild case of COVID and is involved in a car accident three weeks later – and exclude some COVID deaths where someone is in hospital for more than 28 days. The UKHSA data gives us a picture of what is happening now – albeit an imperfect one – while the ONS data takes several weeks to process.

We also need to understand how death certificates work in England and Wales. When somebody passes away, a medical professional completes a death certificate. This includes a field for the “disease or condition directly leading to death” – often called the “underlying cause”. It also includes the option to list one or two diseases or conditions that were not the underlying cause, but which contributed to the death (“contributory causes”).

The data that the ONS publishes shows that, in 2020 and 2021 combined, 157,889 deaths were registered where COVID was mentioned on the death certificate. Of these, 139,839 listed COVID as the underlying cause. In almost 90% of cases where COVID was a factor in somebody’s death, it was considered by medical professionals to be the primary reason they died. So where does the figure of 17,371 COVID deaths come from?

Freedom of information request

This figure originates from a freedom of information request to the Office for National Statistics that asked for the number of deaths where COVID was the only cause of death recorded. This is complicated by the fact that often COVID itself can cause complications, such as severe respiratory difficulties or organ failure, which will then be listed alongside COVID on the death certificate.

To exclude these deaths, the ONS responded by giving the number of deaths where no “pre-existing conditions” were listed on the death certificate. Which comes to 17,371 for the period up to the end of September 2021. But what is a “pre-existing condition”?

Pre-existing conditions and their International Classification of Diseases (ICD) codes

Office for National Statistics

This list is extensive, including high blood pressure, asthma, COPD, diabetes and a wide range of other common conditions. The argument being made by some is that 17,371 is the true number of COVID deaths, because people with these pre-existing conditions, who make up the vast majority of deaths that list COVID on the death certificate, were already sick. But even a cursory glance at the list makes it clear that this will be incorrect for a great many people.

Over a quarter of adults have high blood pressure, 4 million people in England have diabetes and a similar number have asthma. Having one of these conditions is neither a death sentence nor a sign of being in poor health. You almost certainly know several people with one or more of them, or are living with one yourself.

The idea that people with a pre-existing condition are at death’s door is simply untrue. Over half of people aged 50 and over have at least one long-term health condition. But if someone with one of these conditions is unlucky enough to catch COVID and subsequently die, all it takes is for the condition to have some impact for it to end up being listed as a contributory cause on the death certificate.

Let’s take asthma as an example. COVID frequently attacks victims’ lungs, leading them to require ventilation. As a respiratory condition, asthma may well exacerbate these difficulties and will therefore be listed on the death certificate if the person dies. It would be bizarre to claim that the person died of asthma on this basis. Perhaps they would not have died if they didn’t have asthma, but they certainly wouldn’t have died if they hadn’t got COVID.

The vast majority of people who get seriously ill with COVID were living full, independent lives before they were hospitalised. And reasonable estimates suggest that the average number of years of life lost per COVID death is around ten. The idea that people who died from COVID are all extremely ill and would have died soon anyway is not borne out by the facts.

To argue that the deaths from COVID of people with pre-existing conditions don’t count as true COVID deaths is to say that people with pre-existing conditions don’t matter; that their lives are expendable and shouldn’t be considered when assessing the impact of the pandemic. Over 140,000 people with pre-existing conditions have died of COVID in the last two years. We should be mourning this tragic loss of life, not minimising it.

Colin Angus does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

Spread & Containment

As Omicron-specific boosters are in the news, BioNTech to expand German site workforce by 200 employees

BioNTech has added about 200 jobs to its Marburg, Germany manufacturing site since it took it over from Novartis in 2020. This year, it will add another 250, as demand for Covid-19 boosters has led to calls for an omicron-specific vaccine in adults.
Curre

Published

on

BioNTech has added about 200 jobs to its Marburg, Germany manufacturing site since it took it over from Novartis in 2020. This year, it will add another 250, as demand for Covid-19 boosters has led to calls for an omicron-specific vaccine in adults.

Currently, there are around 500 employees at the site, which is north of Frankfurt. The boost is expected to cost around €50 million, or $56.5 million, and will include the addition of office spaces in anticipation of future growth, the company said. The Marburg site has supplied 1.2 billion Covid-19 vaccine doses to the world so far, and a total of 4 billion doses are expected to be doled out by the end of this year.

The news came out of an interview with Bloomberg, a spokesperson for the company confirmed. The $56 million expansion is planned for just the Marburg site alone, the spokesperson confirmed. Before the sale to BioNTech, Novartis invested in the site heavily since 2016, equipping it with capabilities for cell and gene therapy, recombinant proteins, cell culture and viral vector production. In the future, once the need for Covid-19 boosters dies down, BioNTech has said it will other mRNA vaccines, antibody and C&G therapy candidates, as well as its cancer and infectious disease pipeline.

Testing for the vaccine tailored to the pesky variant — which has been deemed more transmissible with less severe symptoms for those that are vaccinated — began this week, BioNTech said along with Pfizer. The trial will test 1,420 healthy adults under the age of 55. Three groups of people, representing different levels of immunity,

In March 2021, Marburg began producing Covid-19 vaccines. It started with the production of mRNA, the active pharmaceutical ingredient for the vaccine. The first batch of doses shipped out in April.

Uğur Şahin

The site has become an example for further growth. BioNTech made waves in the summer of 2021 when it announced plans to collaborate with the African Union to manufacture doses for the continent amid a severe shortage, and in October, the company said that its Rwandan site, which construction is set to begin in the middle of this year, will be modeled after Marburg. Capacity for that one will start at 50 million doses a year, then increase with added manufacturing lines and sites as the project progresses.

CEO Uğur Şahin has already said that the Rwandan site will spin its production into malaria and tuberculosis vaccines once there is a less desperate need for Covid-19 manufacturing.

Read More

Continue Reading

Commodities

Metallum Resources to Present at the Sequire Metals & Mining Conference on January 27, 2022

(TheNewswire) January 26, 2022 TheNewswire – Vancouver, British Columbia – Metallum Resources Inc. (TSXV:MZN) ("Metallum" or the Company") is pleased to announce that it will be presenting virtually at the upcoming Sequire Metals & Mining Conference.

Published

on



(TheNewswire)



January 26, 2022 TheNewswire - Vancouver, British Columbia - Metallum Resources Inc. (TSXV:MZN) ("Metallum" or the Company") is pleased to announce that it will be presenting virtually at the upcoming Sequire Metals & Mining Conference on Thursday, January 27th, at 10:30 AM EST (Track 4).  Kerem Usenmez, President and CEO of Metallum Resources, will be giving the presentation and taking 1x1 meetings.

" I am excited to present at the Sequire Metals and Mining Conference as our first event of the year!  I look forward to telling our story and updating our plans for 2022 as we move forward toward developing the Superior Lake Project and taking steps to re-open the mine.  Zinc and Copper prices have been going up, and Metallum is very well positioned to fast track towards production to supply high quality Zinc and Copper concentrate," stated Metallum's President and CEO, Kerem Usenmez.

Event: Metallum Resources Presentation at the Sequire Metals & Mining Conference

Date: Thursday, January 27th, 2022

Time: 10:30 AM EST

Register to watch the presentation HERE . Investors can also request 1x1 meetings with Metallum Resources CEO on the event website.

Summary of Sequire Metals & Mining Conference

With a massive uptick in the mining industry and electric vehicles on the rise, Sequire is spending the entire day with public mining companies and industry experts exploring possibilities, opportunities, and the latest news.

Qualified Person

The technical information in this news release has been reviewed and approved by Andrew Tims, P.Geo., Exploration Manager of the Company, and a Qualified Person as defined by NI 43-101.

About Metallum

Metallum Resources (TSXV:MZN) is developing its Superior Lake Zinc and Copper Project located in Ontario, Canada.  Superior Lake Project is one of the highest grade zinc Projects in North America (2.35Mt at 17.9% Zn, 0.9% Cu, 0.4 g/t Au and 34 g/t Ag – Equivalent to 1Moz of 13 g/t Au), with a 9 year mine life and After Tax NVP 8% of $253M and IRR at 35% (Zn at US$1.55, Cu at $3.31) .  Metallum is a member of the Gold Group of companies, led by Simon Ridgway.

For further details about the Company and the Superior Lake Project, please visit the Company's website at metallumzinc.com .

ON BEHALF OF THE BOARD

Kerem Usenmez,

President & Chief Executive Officer

Metallum Resources Inc.

Symbol: TSXV-MZN

For further information, contact:

Kerem Usenmez, President & CEO

Tel: 604-688-5288;  Fax: 604-682-1514

Email: info@metallumzinc.com

Website: metallumzinc.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this news release constitute forward-looking statements within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, are forward-looking statements and include, without limitation, statements about the Company's corporate property exploration and development activities. Often, but not always, these forward looking statements can be identified by the use of words such as "estimate", "estimates", "estimated", "potential", "open", "future", "assumed", "projected", "used", "detailed", "has been", "gain", "upgraded", "offset", "limited", "contained", "reflecting", "containing", "remaining", "to be", "periodically", or statements that events, "could" or "should" occur or be achieved and similar expressions, including negative variations.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any results, performance or achievements expressed or implied by forward-looking statements. Such uncertainties and factors include, among others, whether exploration and development of the Company's properties will proceed as planned; changes in general economic conditions and financial markets; the Company or any joint venture partner not having the financial ability to meet its exploration and development goals; risks associated with the results of exploration and development activities, estimation of mineral resources and the geology, grade and continuity of mineral deposits; unanticipated costs and expenses; risks associated with COVID-19 including adverse impacts on the world economy, exploration efforts and the availability of personnel; and such other risks detailed from time to time in the Company's quarterly and annual filings with securities regulators and available under the Company's profile on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

Forward-looking statements contained herein are based on the assumptions, beliefs, expectations and opinions of management, including but not limited to: that the Company's stated goals and planned exploration and development activities will be achieved; that there will be no material adverse change affecting the Company or its properties; and such other assumptions as set out herein. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, investors should not place undue reliance on forward-looking statements.

Copyright (c) 2022 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

Read More

Continue Reading

Trending